Pregnancy Clinical Trial
Official title:
Maternal Opioid Treatment: Human Experimental Research
Children born to women who abuse drugs have a high risk of being born with birth defects and developmental problems. Methadone is a drug that is commonly used for treating opioid dependence. However, its use by a pregnant woman can cause severe withdrawal symptoms in a newborn because of the prenatal exposure. The purpose of this study is to evaluate the effectiveness of buprenorphine, another drug, versus methadone in reducing withdrawal symptoms in children born to opioid-dependent women.
Women who use drugs during pregnancy place their unborn children at high risk for being born
addicted to drugs. Such children may also be born with birth defects and may experience
learning and behavioral problems. Methadone, a synthetic narcotic, is commonly prescribed to
treat opioid addiction. It may not be an optimal solution for opioid-dependent pregnant
women, however, because a large percentage of children born to women taking methadone
experience severe drug withdrawal symptoms at birth that often require medical treatment.
Common opioid withdrawal symptoms, described as neonatal abstinence syndrome (NAS) in
babies, include tremors, irritability, sleep problems, seizures, dehydration, and fever.
Buprenorphine is a medication that has been approved to treat opioid dependence in
individuals who are not pregnant but has not been approved for pregnant individuals. Past
research has shown that use of buprenorphine in pregnant women results in improved birth
outcomes over methadone. The purpose of this study is to evaluate the effectiveness of
buprenorphine versus methadone at reducing opioid withdrawal symptoms in babies born to
opioid-dependent women.
This study will enroll opioid-dependent pregnant women who are 13 to 30 weeks pregnant and
will follow each woman and her child throughout the pregnancy until 6 weeks postpartum. All
participants will undergo an initial screening that will last several hours. Participants
will then be randomly assigned to receive either methadone or buprenorphine on a daily
basis, and will be required to visit the clinic each day to receive their medication.
Outcome measurements will be assessed at weekly study visits throughout the pregnancy, and
will include drug use, HIV risk behaviors, medication dose adequacy and safety, treatment
retention, and psychosocial functioning. Urine samples will be collected 3 times a week, and
blood will be drawn throughout the pregnancy for safety monitoring. Outcome measurements
related to the baby will include head circumference measurement, length of hospital stay,
severity and frequency of withdrawal symptoms, and amount of medication needed to control
withdrawal symptoms.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
| Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
| Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
| Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
| Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
| Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
| Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
| Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
| Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
| Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
| Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
| Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
| Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
| Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
| Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
| Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
| Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
| Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
| Completed |
NCT02566005 -
A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor
|
N/A |